Opinion

Video

Clinical Pearls and Future Perspectives in Advanced NSCLC

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

This is a synopsis of a Peer Exchange video series featuring Benjamin P. Levy, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Solange Peters, MD, PhD, of University Hospital of Lausanne; Joshua K. Sabari, MD, of NYU Langone’s Perlmutter Cancer Center; Edward B. Garon, MD, MS, of UCLA Jonsson Comprehensive Cancer Center; and Marina Chiara Garassino, MD, of University of Chicago Medicine Comprehensive Cancer Center.

In concluding thoughts, speakers Dr Joshua K. Sabari, assistant professor of medicine at NYU Langone Health, Dr Marina Garassino, and Dr Solange Peters emphasized the need for comprehensive molecular profiling to match all patients with non–small cell lung cancer (NSCLC) to optimal targeted therapies or immunotherapies. They consider the phase 3 MARIPOSA trial combining chemotherapy, the anti-EGFR antibody amivantamab, and the EGFR tyrosine kinase inhibitor (TKI) lazertinib very promising for frontline EGFR-mutant NSCLC but await full overall survival data. Dr Garassino highlighted the importance of patient involvement in selecting among emerging regimens balancing efficacy and toxicity.

Dr Peters noted antibody-drug conjugate (ADC) therapies may soon play a greater role, especially after progression on prior targeted and immune therapies, giving community oncologists challenging sequencing decisions requiring expert input. Dr Edward Garon advocated accrual to clinical trials driving recent advances. All speakers stressed the value of a diverse, multidisciplinary team in caring for this complex patient population. Discussants agreed it is an exciting time in lung cancer, with rapid therapeutic evolution requiring new strategies to optimize outcomes. Ongoing studies of novel combinations and ADCs in biomarker-defined subgroups will clarify treatment paradigms. But open communication, referral networks, and trial participation are vital to promote equitable access to the latest scientific breakthroughs for all patients with NSCLC in community and academic settings alike.

*Video synopsis is AI-generated and reviewed by OncLive editorial staff.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.